Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALBUTEROL vs UNI-DUR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing intracellular cyclic AMP, leading to bronchodilation.
UNI-DUR (theophylline) inhibits phosphodiesterase enzymes, leading to increased intracellular c AMP levels. This causes bronchodilation, anti-inflammatory effects (reduced eosinophil infiltration, decreased cytokine release), and enhanced diaphragmatic contractility. It also acts as a weak adenosine receptor antagonist.
Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease,Prevention of exercise-induced bronchospasm,Off-label: Acute hyperkalemia (via nebulization)
Treatment of asthma (chronic stable and acute exacerbations),Chronic obstructive pulmonary disease (COPD) maintenance therapy,Apnea of prematurity (off-label),Ureteral colic (off-label)
2.5 mg (0.5 m L of 0.5% solution) via nebulization every 4-6 hours as needed; or 1-2 inhalations (90 mcg/inhalation) from a metered-dose inhaler every 4-6 hours as needed.
200-400 mg orally every 12 hours; maximum 800 mg daily.
Terminal elimination half-life is 3.8-6.0 hours. In patients with asthma, the half-life is similar, but clinical effect duration is shorter due to rapid redistribution from the receptor site.
Terminal elimination half-life 24-36 hours; prolonged in renal impairment (up to 90 hours).
Primarily metabolized via sulfotransferase (SULT1A3) to inactive sulfate conjugate; minor hepatic metabolism by CYP450 enzymes.
Theophylline is primarily metabolized in the liver by cytochrome P450 enzymes CYP1A2 (major) and CYP2E1, CYP3A4 (minor). It undergoes N-demethylation and oxidation to form metabolites (1-methylxanthine, 3-methylxanthine, 1,3-dimethyluric acid). Approximately 10% is excreted unchanged in urine.
Primarily renal: approximately 60-70% of the dose is excreted in urine as unchanged drug and metabolites (sulfate conjugate) within 24 hours. Fecal excretion accounts for less than 10%.
Primarily renal (70-80%) as unchanged drug and metabolites; 10-15% fecal.
Approximately 52-65% bound to human serum albumin and alpha-1-acid glycoprotein.
95% bound to albumin.
Approximately 1.4-2.0 L/kg. This relatively large Vd indicates extensive distribution into tissues, including lung parenchyma.
Vd 0.2-0.3 L/kg; indicates distribution primarily in extracellular fluid.
Inhaled: 10-20% of the dose reaches the lungs systemically; Oral: approximately 28-40% (due to first-pass metabolism to sulfate conjugate); Subcutaneous: nearly 100%.
Oral: 85-95% (immediate-release); 70-80% (extended-release).
No dosage adjustment required for renal impairment.
GFR 30-50 m L/min: 200 mg every 12 hours; GFR <30 m L/min: 200 mg every 24 hours; hemodialysis: 200 mg after dialysis.
No specific guidelines; use with caution in severe hepatic impairment due to potential for increased systemic exposure.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg every 12 hours; Child-Pugh C: 200 mg every 24 hours.
Nebulized: 0.05-0.15 mg/kg/dose (minimum 1.25 mg) every 4-6 hours as needed. MDI: 1-2 inhalations (90 mcg/inhalation) every 4-6 hours as needed. Maximum: 12 inhalations/day.
5-10 mg/kg orally every 12 hours; maximum 400 mg daily.
Initiate at lower end of dosing range; monitor for tremors, tachycardia, and hypertension. No specific dose adjustment required.
Initiate at 200 mg every 12 hours; increase cautiously, monitor renal function.
None.
WARNING: Life-threatening adverse events, including seizures, cardiac arrhythmias, and respiratory arrest, can occur with theophylline toxicity. Serum theophylline levels must be monitored closely, and dosing adjusted to maintain therapeutic range (5-15 mcg/m L). Concurrent use with other xanthines (e.g., caffeine) is contraindicated.
Paradoxical bronchospasm may occur with excessive use,Cardiovascular effects: increased heart rate, hypertension, arrhythmias,Hypokalemia may occur with high doses,Immediate hypersensitivity reactions possible,Use caution in patients with cardiovascular disorders, hyperthyroidism, diabetes, or seizure disorders
Therapeutic drug monitoring required due to narrow therapeutic index. Caution in patients with hepatic impairment, heart failure, pneumonia, elderly, and fever (prolonged half-life). Drug interactions with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) and inducers (e.g., smoking, rifampin). Seizure risk at high levels. Cardiotoxicity (atrial/ventricular arrhythmias).
Hypersensitivity to albuterol or any component of the formulation
Hypersensitivity to theophylline or any component. Concurrent use with ephedrine or other xanthines. Active seizure disorder (relative). Uncontrolled cardiac arrhythmias. Severe hepatic impairment.
No clinically significant food interactions. Caffeine may potentiate stimulant effects; avoid excessive caffeine intake.
Food does not affect absorption significantly; however, consistent dietary caffeine intake may increase side effects. A high-protein, low-carbohydrate diet can decrease theophylline clearance; avoid drastic dietary changes.
FDA Pregnancy Category C. In first trimester, no increased risk of major congenital anomalies based on human data. Second and third trimesters: risk of maternal tachycardia, hyperglycemia; fetal tachycardia, hypoglycemia at birth if used near term. Possible association with gastroschisis in first trimester from some studies, but not confirmed.
Pregnancy Category C. First trimester: no adequate studies, potential risk based on animal data. Second and third trimesters: may cause fetal harm including decreased uterine blood flow, growth restriction, and premature labor inhibition. Avoid use unless benefit outweighs risk.
Excreted into breast milk in low concentrations; M/P ratio not established. Limited data suggest no adverse effects in infants. American Academy of Pediatrics considers compatible with breastfeeding. Use with caution in preterm infants or those with tachycardia.
Excreted in human milk; M/P ratio not established. Potential for serious adverse reactions in nursing infants. Decision to discontinue nursing or drug based on importance to mother.
No specific dose adjustment required for pregnancy. Pharmacokinetics may be altered due to increased plasma volume and renal clearance, but clinical significance is minimal. Use lowest effective dose to control symptoms.
No standard dose adjustments. Increased clearance and volume of distribution during pregnancy may require dose titration based on clinical response and serum drug levels if applicable.
Monitor for paradoxical bronchospasm; use with caution in patients with cardiovascular disorders due to beta-adrenergic stimulation; may cause hypokalemia with high doses; combine with ipratropium for acute exacerbations; not recommended for long-term control without anti-inflammatory therapy.
UNI-DUR (theophylline extended-release) requires monitoring of serum theophylline concentrations to maintain efficacy and avoid toxicity; therapeutic range is 5-15 mcg/m L. Avoid use in patients with active peptic ulcer disease or seizure disorders. Dosage adjustments needed in hepatic impairment, heart failure, and with concurrent use of drugs that affect CYP1A2 and CYP3A4.
Use only as prescribed; do not exceed recommended dose.,Rinse mouth after use to prevent oral candidiasis (if using with corticosteroid), but albuterol alone does not require rinsing.,Seek emergency care if symptoms worsen or inhaler provides less relief.,Shake inhaler well before each use; use spacer if available for better delivery.,Monitor for palpitations, tremors, or nervousness; report if severe.
Take UNI-DUR exactly as prescribed, at the same time each day, with or without food.,Do not crush or chew the tablets; swallow whole.,Avoid smoking and limit caffeine intake as they can alter theophylline levels.,Report symptoms of toxicity such as nausea, vomiting, insomnia, palpitations, or seizures.,Do not change brands or formulations without consulting your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALBUTEROL vs UNI-DUR, answered by our medical review team.
ALBUTEROL is a Beta-2 Adrenergic Agonist (Bronchodilator) that works by Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing intracellular cyclic AMP, leading to bronchodilation.. UNI-DUR is a Methylxanthine Bronchodilator that works by UNI-DUR (theophylline) inhibits phosphodiesterase enzymes, leading to increased intracellular c AMP levels. This causes bronchodilation, anti-inflammatory effects (reduced eosinophil infiltration, decreased cytokine release), and enhanced diaphragmatic contractility. It also acts as a weak adenosine receptor antagonist.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALBUTEROL and UNI-DUR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALBUTEROL is: 2.5 mg (0.5 m L of 0.5% solution) via nebulization every 4-6 hours as needed; or 1-2 inhalations (90 mcg/inhalation) from a metered-dose inhaler every 4-6 hours as needed.. The standard adult dose of UNI-DUR is: 200-400 mg orally every 12 hours; maximum 800 mg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALBUTEROL and UNI-DUR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALBUTEROL is classified as Category C. FDA Pregnancy Category C. In first trimester, no increased risk of major congenital anomalies based on human data. Second and third trimesters: risk of maternal tachycardia, hyperg. UNI-DUR is classified as Category C. Pregnancy Category C. First trimester: no adequate studies, potential risk based on animal data. Second and third trimesters: may cause fetal harm including decreased uterine blood. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.